{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062045","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.815028+00:00","generated_at":"2026-06-08T06:45:46.315389+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Athira Pharma Q3 net loss widens to $32.7M, cash at $172.9M; LIFT-AD enrollment expected Q1 2024","bullets":["Net loss of $32.7M ($0.87/share) vs $20.2M ($0.53/share) in Q3 2022; R&D expenses up $10.2M to $27.2M.","Cash, cash equivalents and investments at $172.9M as of Sept 30, down from $245.2M at Dec 31, 2022; operating cash burn $74.5M YTD.","Phase 2/3 LIFT-AD trial enrollment for fosgonimeton expected complete by Q1 2024; topline data anticipated in H2 2024.","ATH-1105 (oral ALS candidate) IND-enabling studies ongoing; first-in-human study expected in H1 2024.","New preclinical fosgonimeton data to be presented at Neuroscience 2023 (Nov 11-15) in Washington, D.C."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062045","json":"https://secwatch.observer/filing/0000950170-23-062045.json","markdown":"https://secwatch.observer/filing/0000950170-23-062045.md","text":"https://secwatch.observer/filing/0000950170-23-062045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023062045/0000950170-23-062045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023062045/atha-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:45:46.315389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a91513617e4f68a0465f02e229c5666c12ee80a","claim":"LeonaBio, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023062045/0000950170-23-062045-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}